Table 2.

Median overall survival and progression-free survival estimates according to hyperprogression status and line of therapy.

	N a	Median overall survival months (95% CI)	Median PFS months (95% CI)
First-line
With hyperprogression	13	4.3 (2.5-n/a)	1.5 (1.4-n/a)
Without hyperprogression	1901	18.6 (17.1-19.8)	7.2 (7.0-7.5)
Second- or later-line
With hyperprogression	106	6.1 (4.4-8.6)	1.4 (1.4-1.4)
Without hyperprogression	1101	16.2 (15.5-18.0)	4.1 (3.5-4.2)

^a N at the day 42 landmark.

Abbreviation: PFS, progression-free survival.